A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 10 Apr 2017

At a glance

  • Drugs Quizartinib (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 04 Apr 2017 Planned End Date changed from 31 Mar 2018 to 1 Jul 2017.
    • 04 Apr 2017 Planned primary completion date changed from 1 Feb 2017 to 1 Jul 2017.
    • 03 Apr 2017 Planned End Date changed to 31 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top